ACM
DNTH icon

Aquatic Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Aquatic Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,829
Closed -$694K – 1477
2025
Q4 		$694K Buy
+16,829
New +$652K 0.02% 645
2025
Q3 		– Sell
-3,187
Closed -$59.4K – 1454
2025
Q2 		$59.4K Buy
+3,187
New +$59.8K ﹤0.01% 1131

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aquatic Capital Management's DNTH Position: Q1 2026 in Review

Aquatic Capital Management sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 16,829 shares — an estimated $694K sold.

Aquatic Capital Management first reported a position in DNTH in Q2 2025 and held it in 2 quarters. The position peaked at $694K in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Aquatic Capital Management reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 16,829 Dianthus Therapeutics shares in Q1 2026, an estimated $694K.
  • Aquatic Capital Management first reported a position in Dianthus Therapeutics in Q2 2025 and held it in 2 quarters.
  • Aquatic Capital Management's Dianthus Therapeutics position peaked at $694K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.